There is no excerpt because this is a protected post.
HTA Council Preliminary Recommendation on irbesartan/amlodipine (fixed-dose combination) [150 mg/5 mg tablet, 300 mg/5 mg tablet, and 300 mg/10 mg tablet] for the treatment of essential hypertension
As of 06 October 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of irbesartan/amlodipine (fixed-dose combination) [150 mg/5 mg tablet, 300 mg/5 mg tablet, and 300 mg/10 mg tablet] for the treatment of essential hypertension. The HTA Council hereby releases its preliminary recommendation on the said health technology continue reading : HTA Council Preliminary Recommendation on irbesartan/amlodipine (fixed-dose combination) [150 mg/5 mg tablet, 300 mg/5 mg tablet, and 300 mg/10 mg tablet] for the treatment of essential hypertension
HTA Council Preliminary Recommendation on fluticasone furoate/umeclidinium/vilanterol [100 mcg/62.5 mcg/25 mcg per pre-dispensed dose, dry powder for inhalation] and budesonide/glycopyrronium/formoterol fumarate [160 mcg/7.2 mcg/4.8 mcg per actuation, pressurized metered-dose inhaler] for the treatment of patients with chronic obstructive pulmonary disease
On 29 September 2026, the HTA Council completed the evidence appraisal of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) [100 mcg/62.5 mcg/25 mcg per pre-dispensed dose, dry powder inhalation (DPI)] and budesonide/glycopyrronium/formoterol fumarate (BUD/GLY/FORM) [160 mcg/7.2 mcg/4.8 mcg per actuation, pressurized metered-dose inhaler (MDI)] for the initial maintenance treatment and follow-up maintenance treatment of patients with chronic obstructive pulmonary continue reading : HTA Council Preliminary Recommendation on fluticasone furoate/umeclidinium/vilanterol [100 mcg/62.5 mcg/25 mcg per pre-dispensed dose, dry powder for inhalation] and budesonide/glycopyrronium/formoterol fumarate [160 mcg/7.2 mcg/4.8 mcg per actuation, pressurized metered-dose inhaler] for the treatment of patients with chronic obstructive pulmonary disease
HTA Council Preliminary Recommendation on bevacizumab [25 mg/mL concentrate for solution for intravenous (IV) infusion] in combination with a platinum-taxane doublet chemotherapy, specifically cisplatin [1 mg/mL solution for IV infusion] or carboplatin [10 mg/mL solution for IV infusion; lyophilized powder for injection in 150 mg and 450 mg vial] + paclitaxel [6 mg/mL solution for IV infusion] for the treatment of metastatic, persistent or recurrent cervical cancer
As of 29 September 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of bevacizumab [25 mg/mL concentrate for solution for intravenous (IV) infusion] in combination with a platinum-taxane doublet chemotherapy, specifically cisplatin [1 mg/mL solution for IV infusion] or carboplatin [10 mg/mL solution for IV infusion; lyophilized powder continue reading : HTA Council Preliminary Recommendation on bevacizumab [25 mg/mL concentrate for solution for intravenous (IV) infusion] in combination with a platinum-taxane doublet chemotherapy, specifically cisplatin [1 mg/mL solution for IV infusion] or carboplatin [10 mg/mL solution for IV infusion; lyophilized powder for injection in 150 mg and 450 mg vial] + paclitaxel [6 mg/mL solution for IV infusion] for the treatment of metastatic, persistent or recurrent cervical cancer
HTA Council Preliminary Recommendation on alendronic acid (as sodium alendronate) 70 mg effervescent tablet for the treatment of postmenopausal osteoporosis
As of 24 September 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of alendronic acid (as sodium alendronate) 70 mg effervescent tablet for the treatment of postmenopausal osteoporosis. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 24 continue reading : HTA Council Preliminary Recommendation on alendronic acid (as sodium alendronate) 70 mg effervescent tablet for the treatment of postmenopausal osteoporosis